Skip to main content
Premium Trial:

Request an Annual Quote

NHLBI Warfarin Trial to Use Trimgen Tests

NEW YORK (GenomeWeb News) — The National Heart Lung and Blood Institute will use TrimGen's eQ-PCR Warfarin Genotyping Kit in a clinical trial designed to find out if a gene-based strategy will benefit patients who are at high risk for warfarin sensitivity.

Sensitivity to the blood-thinning drug can result in a higher risk of thromboembolism and bleeding, and can lead doctors to discontinue the therapy early.

The multi-center study, Clarification of Optimal Anticoagulation through Genetics (COAG), will compare two warfarin dosing approaches, including one group that will receive genotype-guided dosing and another group that will receive dosing using clinical data.

Trimgen said it will contribute the tests used for the study, which will begin in April 2009 and is expected to last until 2012.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.